 BOSTON and ZUG, Switzerland-- BUSINESS WIRE --Vertex Pharmaceuticals Incorporated Nasdaq: VRTX and CRISPR Therapeutics Nasdaq: CRSP today announced an oral, encore presentation of clinical data from patients with sickle cell disease SCD or transfusion-dependent beta-thalassemia TDT treated with the investigational therapy exagamglogene autotemcel exa-cel in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study. Vertex will also present new health economics and outcomes research from multiple studies in patients with SCD and TDT. 